$OABI SIGNS LILLY DEAL WORTH UP TO $370M
OmniAb entered a global collaboration and licensing agreement with Eli Lilly for a new ion channel drug discovery program.
OmniAb will receive an upfront payment and is eligible for up to $370M in research, development and commercial milestones, plus tiered royalties on global net sales. The target and therapeutic modality were not disclosed.